
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks Inc exhibits a promising financial outlook due to its robust clinical development pipeline, highlighted by the significant improvements in progression-free survival (PFS) and overall survival (OS) demonstrated by its lead clinical candidate, Ziihera, in combination with chemotherapy. The company's unique position as a royalty-driven organization is further strengthened by anticipated high-margin revenue streams, including tiered royalties from JAZZ's peak sales estimates for Ziihera and additional mid-single-digit royalties from Johnson & Johnson. Furthermore, Zymeworks maintains a solid financial foundation with $299 million in cash and $440 million associated with near-term milestones, providing a strong base for future growth and development.
Bears say
Zymeworks Inc faces significant risks that contribute to a negative outlook on its stock, particularly due to potential failures in clinical trials related to efficacy and safety for its lead candidate, zanidatamab, as well as challenges in securing manufacturing scalability. Additionally, the company's reliance on external financing in a capital-intensive biotechnology environment raises concerns about insolvency if market conditions deteriorate or if it fails to raise sufficient funds, which could also lead to substantial dilution for current shareholders. Moreover, recent adjustments to revenue forecasts stemming from the discontinuation of certain pipeline assets further exacerbate concerns regarding the company's future financial performance and market competitiveness.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares